e-Therapeutics plc (ETX) Ordinary 0.1p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
E-Therapeutics enters collaboration with Arcturis Data
2 November 2023 14:32
(Sharecast News) - E-Therapeutics announced a strategic collaboration with Arcturis Data on Thursday - a prominent UK data company known for its high-quality, real-world data platform.
-
Eight new patent applications filed by e-therapeutics
1 August 2022 13:29
(Sharecast News) - Computational drug discovery and development company e-therapeutics announced the filing of eight further patent applications in the United States on Monday, to protect innovation arising...
-
E-therapeutics reaches 'key milestone' in Galapagos collaboration
12 April 2022 13:26
(Sharecast News) - Drug discovery specialist E-therapeutics announced on Tuesday that it has reached a key milestone in its collaboration with Galapagos.
-
E-therapeutics finance chief stepping down due to family
22 November 2021 14:16
(Sharecast News) - Drug discovery company E-therapeutics announced on Monday that Karl Keegan was stepping down from his non-board role as chief financial officer, to focus on "extremely difficult"...
-
eTherapeutics CFO to stand down on 31 December
22 November 2021 10:20
(Sharecast News) - Drug discovery e-Therapeutics revealed on Monday that chief financial officer Karl Keegan will step down from the role in order to focus on "extremely difficult family...
-
E-therapeutics meets 'key milestone' in Galapagos collaboration
2 July 2021 13:47
(Sharecast News) - E-therapeutics has met a key milestone in its collaboration with Galapagos, a commercial-stage company specialising in the discovery and development of small-molecule medicines with novel...
-
E-therapeutics brings in Alison Gallafent as head of IP
2 June 2021 09:42
(Sharecast News) - Drug discovery company e-therapeutics announced the appointment of Alison Gallafent as its head of intellectual property on Wednesday.
-
E-therapeutics raises £22.5m to expand capabilities and pipeline
14 May 2021 14:20
(Sharecast News) - E-therapeutics has completed a placing, subscription and retail offer via PrimaryBid, it announced on Friday, conditionally raising gross proceeds of £22.5m to help expand its drug...
-
E-therapeutics to receive two milestone payments from Galapagos
23 April 2021 10:18
(Sharecast News) - E-therapeutics has met two key milestones in its collaboration with small-molecule medicines specialist Galapagos, it announced on Friday.
Company announcements Announcements
-
Total Voting Rights
31 January 2024 16:30
e-Therapeutics
-
Exercise of Options and Issue of Equity
24 January 2024 10:04
e-Therapeutics
-
Business Update
16 January 2024 07:00
e-Therapeutics
-
Director Dealing and Issue of Equity
9 January 2024 16:04
e-Therapeutics
-
Update on OTCQX Market Listing
27 December 2023 07:00
e-Therapeutics
-
Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
13 November 2023 09:05
e-Therapeutics
-
Strategic RWE collaboration with Arcturis
2 November 2023 07:00
e-Therapeutics
-
Interim results for the six months to 31 July 2023
26 October 2023 07:38
e-Therapeutics
-
Notice of Interim Results
19 October 2023 09:54
e-Therapeutics
-
Senior Management Update
20 September 2023 07:00
e-Therapeutics
-
Exercise of Options and Issue of Equity
7 September 2023 11:47
e-Therapeutics
-
Total Voting Rights
31 July 2023 16:30
e-Therapeutics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.